Rothschild Investment LLC Purchases 282 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Rothschild Investment LLC boosted its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 3.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,655 shares of the exchange traded fund’s stock after purchasing an additional 282 shares during the quarter. Rothschild Investment LLC’s holdings in SPDR S&P Biotech ETF were worth $870,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of XBI. Howard Capital Management Group LLC increased its position in shares of SPDR S&P Biotech ETF by 2.6% during the third quarter. Howard Capital Management Group LLC now owns 248,114 shares of the exchange traded fund’s stock worth $24,514,000 after acquiring an additional 6,188 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in SPDR S&P Biotech ETF by 74.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 4,002 shares of the exchange traded fund’s stock valued at $395,000 after purchasing an additional 1,711 shares during the last quarter. Mount Yale Investment Advisors LLC increased its holdings in SPDR S&P Biotech ETF by 12.5% during the 3rd quarter. Mount Yale Investment Advisors LLC now owns 2,842 shares of the exchange traded fund’s stock worth $281,000 after purchasing an additional 315 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in SPDR S&P Biotech ETF by 16.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,390 shares of the exchange traded fund’s stock worth $2,113,000 after purchasing an additional 2,997 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of SPDR S&P Biotech ETF by 4.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 118,563 shares of the exchange traded fund’s stock worth $11,714,000 after purchasing an additional 4,625 shares during the last quarter.

SPDR S&P Biotech ETF Stock Down 1.7 %

Shares of NYSEARCA:XBI opened at $90.11 on Tuesday. The business’s 50 day moving average is $91.26 and its 200 day moving average is $95.97. SPDR S&P Biotech ETF has a 12-month low of $81.14 and a 12-month high of $105.47. The stock has a market cap of $6.87 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.